Results 1 to 10 of about 1,312,400 (160)
An epigenetic biomarker of aging for lifespan and healthspan
Identifying reliable biomarkers of aging is a major goal in geroscience. While the first generation of epigenetic biomarkers of aging were developed using chronological age as a surrogate for biological age, we hypothesized that incorporation of ...
M. Levine+17 more
semanticscholar +3 more sources
DunedinPACE, a DNA methylation biomarker of the pace of aging
Background: Measures to quantify changes in the pace of biological aging in response to intervention are needed to evaluate geroprotective interventions for humans.
Daniel W Belsky+19 more
semanticscholar +1 more source
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology.
N. Ashton+14 more
semanticscholar +1 more source
Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and laboratory predictors for progression towards severe and fatal forms of this illness.
B. Henry+4 more
semanticscholar +1 more source
Calprotectin: from biomarker to biological function
The incidence of inflammatory bowel diseases (IBD) emerged with Westernisation of dietary habits worldwide. Crohn’s disease and ulcerative colitis are chronic debilitating conditions that afflict individuals with substantial morbidity and challenge ...
A. Jukic+4 more
semanticscholar +1 more source
Metagenomic biomarker discovery and explanation
This study describes and validates a new method for metagenomic biomarker discovery by way of class comparison, tests of biological consistency and effect size estimation.
N. Segata+6 more
semanticscholar +1 more source
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Normal somatic cells invariably enter a state of irreversibly arrested growth and altered function after a finite number of divisions. This process, termed replicative senescence, is thought to be a tumor-suppressive mechanism and an underlying cause of ...
Goberdhan P Dimri+9 more
semanticscholar +1 more source
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive ...
T. Chan+6 more
semanticscholar +1 more source
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing-based estimates of TMB have largely replaced whole-exome sequencing-derived TMB in the ...
D. Sha+5 more
semanticscholar +1 more source
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of ...
Weijie Cao+6 more
semanticscholar +1 more source